

# Sixty years of the Bruce protocol: reappraising the contemporary role of exercise stress testing with electrocardiographic monitoring

Eduardo M. Vilela<sup>a,\*</sup>, Cátia Oliveira<sup>b,c</sup>, Cláudia Oliveira<sup>a</sup>, Susana Torres<sup>a</sup>, Francisco Sampaio<sup>a,d</sup>, João Primo<sup>a</sup>, José Ribeiro<sup>a</sup>, Madalena Teixeira<sup>a</sup>, Marco Oliveira<sup>a</sup>, Nuno Bettencourt<sup>d</sup>, Sofia Viamonte<sup>e</sup>, Ricardo Fontes-Carvalho<sup>a,d</sup>

**Abstract** The cardiovascular response to exercise has long been a focus of interest. Over a century ago, the first descriptions of electrocardiographic changes occurring during exercise highlighted the possible relevance of this dynamic assessment. In this background, the inception of the Bruce protocol circa 60 years ago allowed for a major leap in this field by providing a standardized framework with which to address this issue, by means of an integrated and structured methodology. Since then, exercise stress testing with electrocardiographic monitoring (ExECG) has become one of the most widely appraised tests in cardiovascular medicine. Notably, past few decades have been profoundly marked by substantial advances in the approach to cardiovascular disease, challenging prior notions concerning both its physiopathology and overall management. Among these, the ever-evolving presentations of cardiovascular disease coupled with the development and implementation of several novel diagnostic modalities (both invasive and noninvasive) has led to a shifting paradigm in the application of ExECG. This technique, however, has continuously shown to be of added value across various momentums of the cardiovascular continuum, as depicted in several contemporary guidelines. This review provides a pragmatical reflexion on the development of ExECG, presenting a comprehensive overview concerning the current role of this modality, its challenges, and its future perspectives.

**Keywords:** cardiovascular prevention, electrocardiography, exercise testing

## Introduction

Throughout the decades, substantial improvements have been made in the management of cardiovascular disease (CVD), stemming from advances from a wide range of areas encompassing preventive, diagnostic, and therapeutic modalities.<sup>1-4</sup> Although these have continuously changed the landscape in cardiovascular medicine, these pathologies, nonetheless, still comprise a major cause of morbidity and mortality worldwide.<sup>1,5</sup> As such, the quest for strategies to address CVD remains an area of great interest.<sup>3,6,7</sup> While, as stated above, the contribution from diverse fields should be highlighted as being central to current concepts regarding CVD (across its various presentations), the advent of different diagnostic modalities has been instrumental for both enhancements on the understanding of its physiopathology and in overall improvements in patient care.<sup>7-10</sup>

A major milestone in cardiovascular medicine pertains to the introduction of the electrocardiogram (ECG).<sup>3,11,12</sup> Building on previous studies, this technology, providing a graphical representation of cardiac electrical activity, was first introduced more than a century ago.<sup>11,12</sup> Since then subsequent improvements have rendered it fundamental across several CVDs, from ischemic heart disease (IHD) to rhythm and conduction disorders.<sup>12-16</sup> This concept has since been incorporated in other methodologies such as heart rhythm monitoring and the assessment of the cardiac response to exercise, with technological developments allowing for novel insights.<sup>15,17,18</sup> Notably, already in the early days of its use, the electrocardiographic response to exercise was a focus of interest.<sup>19-21</sup> Since these first descriptions, different protocols were applied to provide a dynamic overview of the cardiovascular system during exercise.<sup>19,20</sup> Among these, the Bruce protocol, first introduced 60 years ago, was to be particularly important.<sup>22,23</sup>

This review provides an overview on the development of exercise stress testing with electrocardiographic monitoring (ExECG) with the background of the Bruce protocol while discussing the contemporary role of this test, its challenges, and future perspectives.

## Exercise and CVD

Exercise has a major impact on the cardiovascular system, both acutely and chronically.<sup>24-28</sup> Albeit a detailed account of the myriad cardiovascular adaptations to exercise is beyond the scope of this review, a brief discussion of its acute effects should be recalled when exploring exercise stress testing.<sup>29-32</sup>

During acute (aerobic) exercise, there is a progressive increase in cardiac output (CO) in the background of a diverse and integrated physiological response, encompassing changes in the heart and vessels per se as well as those in the respiratory (such as

<sup>a</sup> Cardiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, <sup>b</sup> Cardiology Department, Hospital de Braga, Braga, Portugal, <sup>c</sup> Faculty of Medicine, Minho University, Braga, Portugal, <sup>d</sup> Cardiovascular Research Center (UniC@RISE), Faculty of Medicine, University of Porto, Porto, Portugal, <sup>e</sup> North Rehabilitation Centre, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

\* Corresponding author. Cardiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia, Portugal. E-mail address: eduardomvilela@gmail.com (Eduardo M. Vilela).

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associação Porto Biomedical/Porto Biomedical Society.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Porto Biomed. J. (2023) 8:5(e235)

Received: 2 September 2023 / Accepted: 18 September 2023

<http://dx.doi.org/10.1097/j.pbj.0000000000000235>

increases in ventilation), musculoskeletal (with increases in muscle contraction), and autonomic nervous systems.<sup>24,30,33</sup> These are reflected in increases in both heart rate (HR) and stroke volume (determinants of CO).<sup>30,33</sup> Given these phenomena, systolic blood pressure (BP) is expected to increase during exercise, whereas diastolic BP is predominantly maintained (with slight changes being considered within the range of normality).<sup>31,34</sup> Importantly, these responses to exercise can vary in their magnitude because of several factors (among which age and genetic background).<sup>35,36</sup> Furthermore, these can also be modulated by the effects of training and be disrupted by pathological processes or medications.<sup>17,26,33,37,38</sup> During ExECG, these responses may be monitored, providing insights into the cardiovascular response and being of relevance (as detailed below) in various clinical settings.<sup>15-17,26,39-41</sup> For example, for HR monitoring, its response can be of use when considering chronotropic incompetence as a cause of effort intolerance.<sup>15</sup> As for BP, an inability of systolic BP to increase (or a decrease during exercise) may be a harbinger of increased risk in entities ranging from aortic valve disease to hypertrophic cardiomyopathy.<sup>26,37,42</sup> On the other hand, although not recommended for the routine assessment of arterial hypertension (because of limitations such as lack of standardized definitions and methodology and the possible influence of cardiorespiratory fitness [CRF] levels), an exaggerated BP response to exercise can suggest an increased risk for the development of hypertension and thus lead to further monitoring.<sup>33,43-45</sup>

Of note, the incorporation of ventilation and gas exchange data into ExECG (i.e., cardiopulmonary exercise stress testing [CPET]) provides a plethora of information, allowing a detailed objective analysis of functional capacity and of factors leading to potential exercise intolerance, being a pivotal test in settings ranging from exercise prescription to the assessment of heart failure.<sup>34,46-50</sup> While CPET continues to evolve and encompass applications across a range of areas, the use of ExECG (i.e., without gas exchange parameters) may still provide crucial information in the assessment of CVD (Fig. 1).

## Exercise stress testing with electrocardiographic monitoring: contemporary paradigm

### Overview

The interaction between exercise and CVD has long been a focus of interest.<sup>20,23,51-53</sup> Over a century ago, observations were made that patients with CVD could present ST segment changes in the ECG, namely during physical effort, thus creating a base on which further study would ensue.<sup>20,21,23,53</sup> Although pioneering works attempted to provide a framework for this assessment, a

breakthrough occurred with the development of what would go on to become one of the most widely appraised tests in cardiovascular medicine, the use of ExECG with the Bruce protocol.<sup>20,22,23</sup> First presented by the late Robert Arthur Bruce (who, among other achievements, was to be the first chief of Cardiology at the University of Washington School of Medicine, now sometimes being recalled as the Father of Exercise Cardiology) and colleagues, this protocol provided a standardized rigorous methodology for the dynamic assessment of CVD.<sup>22,23,52,54,55</sup> Among some of its strengths, the presence of multiple stages (in comparison with a single-stage approach), the assessment of various participants (to develop standards for subsequent findings), and the multiparametric approach should be recalled.<sup>23,54</sup> Although possible pitfalls in subgroups such as the elderly, obese, and pediatric populations coupled with limitations such as the concept that relatively large increments between stages might lead to difficulties in estimating functional capacity and the fact that other protocols have since been introduced, this was, nevertheless, instrumental in this field.<sup>23,52</sup>

Since the introduction of what would mature into the “Bruce protocol,” many changes in CVD, including its presentations and assessment, have elapsed.<sup>1,2,5,56</sup> While the central role of the twelve-lead ECG (without an associated exercise component) in settings such as acute chest pain or when considering rhythm disturbances and interventions (such as cardiac resynchronization therapy) are consensual, the utility of ExECG has undergone substantial changes.<sup>4,13,15,16,39,57,58</sup> These resonate deeply with current recommendations regarding chronic coronary syndromes where the utility of ExECG in the diagnosis of IHD has progressively been superseded by imaging modalities because of issues related to both sensitivity and specificity.<sup>4,16,59,60</sup> Interestingly, while data reinforce the limitations of this examination in the assessment of suspected IHD (a hitherto classical indication), contemporary guidelines also acknowledge the potential of ExECG in several scenarios (Fig. 1).<sup>4,15,16,26,39,40,42,57,61,62</sup>

### IHD

Although the diagnostic assessment of IHD is a classical indication of ExECG, as detailed above, there are increasing data attesting to its limitations.<sup>4,16,52,63,64</sup> In this regard, a seminal meta-analysis showed a better performance of imaging modalities when compared with ExECG, with the latter having a limited ability in diagnosing or ruling out anatomically significant coronary artery disease (CAD).<sup>65</sup> These are illustrated in the guidelines of the European Society of Cardiology (ESC), which have downgraded ExECG for diagnostic purposes (presenting a class IIb, level B recommendation) when compared with its




Figure 1. Overview of some of the potential applications of exercise stress testing with electrocardiographic monitoring.

previous iteration.<sup>16,58</sup> Similarly, British recommendations also underscore the use of imaging (notably computed tomography) in the diagnosis of CAD.<sup>66</sup> Albeit this, the ESC guidelines showcase the role of ExECG in those with suspected CAD to assess parameters such as arrhythmias, BP response, exercise tolerance, and symptoms while also considering that it could be of use for risk assessment in selected patients (as a class I, level C recommendation).<sup>16</sup>

American guidelines on chest pain, on the other hand, while also highlighting the role of imaging modalities, nonetheless, present a relatively broader applicability of ExECG in the diagnosis of CAD.<sup>57</sup> In the setting of stable chest pain in intermediate-high risk patients without prior CAD diagnosis, ExECG may be used in those able to exercise and with an interpretable ECG (class IIa, level B-R recommendation), although imaging modalities are still preferred (class I, levels of evidence A to B-R).<sup>57</sup> For those at low risk, ExECG may also be considered (class IIa, level B-NR recommendation).<sup>57</sup> Recently, a report on multimodality appropriate use criteria in the setting of chronic coronary syndromes has also detailed some possible uses of ExECG.<sup>4</sup> These also detail some of the possible uses of ExECG in chest pain assessment while highlighting its utility in scenarios such as arrhythmia and exercise assessment.<sup>4</sup> Notably, this possible ancillary role of ExECG is also echoed in American guidelines for patients with chronic coronary syndromes.<sup>67</sup>

Some hindrances should be acknowledged when considering the use of ExECG in the assessment of suspected CAD.<sup>16,57,63,68,69</sup> First, technical issues such as ECG quality or baseline abnormalities (including left bundle branch block or ventricular pacing, both of which could affect interpretation) should be considered.<sup>26,52,57</sup> Second, the use of medications (namely anti-ischemic agents) as well as pathologies such as anemia and valvular heart disease may influence repolarization findings.<sup>70</sup> Moreover, workload levels performed and ensuing HR should also be taken into consideration.<sup>17,70,71</sup> Third, there are still some questions regarding the overall use of ExECG in different subgroups.<sup>68,69,71</sup> Although different studies support the added value of imaging in the face of ExECG, two randomized controlled trials showed that in women at low and moderate risk (respectively), an ExECG-based strategy provided similar efficacy to one based on imaging (with nuclear and echocardiographic assessments, respectively).<sup>63-65,68,69</sup> Finally, data have emerged showing that ECG abnormalities may be associated with an increased risk of events in those with normal imaging findings.<sup>72,73</sup> Although further data are needed to fully clarify these findings, and the fact that factors such as functional capacity and BP should also be equated, these, however, show that there are still unmet issues relating to this technique.<sup>72-75</sup>

As shown above, ExECG may still be of use in the diagnostic process of selected patients with suspected CAD.<sup>4,16,57</sup> Albeit this, in this setting, its role has progressively focused on providing a comprehensive assessment able to detail relevant ancillary data regarding several facets of the cardiovascular response to physical effort.<sup>16,59,60</sup>

### **Cardiac rehabilitation and exercise prescription**

Given its integrative nature, ExECG may be particularly relevant in the evaluation of the exercise response in patients with CVD.<sup>4,16,26,76,77</sup> This encompasses the detection of possible cardiovascular abnormalities (for symptoms, but also arrhythmias and the BP response) while also allowing for an objective measure of the individual's functional capacity.<sup>26,78,79</sup> In

addition, an exercise test is also paramount for exercise prescription.<sup>26,48,76,77</sup> While, for this latter point, it has been well-explored that CPET can be of major value for a physiological approach to prescription (by allowing, among others, assessment of the ventilatory thresholds), ExECG may still be relevant (namely in contexts without access to CPET).<sup>48,76</sup> Though with its limitations (as expertly detailed in a recent statement by the European Association of Preventive Cardiology [EAPC]), the use of parameters such as HR and peak workload may still allow insights into exercise prescription (being part of the minimal standards for aerobic exercise prescription).<sup>48,76</sup>

The role of a functional assessment in exercise prescription among those with CVD is depicted in current guidelines.<sup>26,48</sup> The guidelines of the ESC recommend a risk-stratification approach (encompassing an exercise test) for patients with CAD while this concept is also echoed in those of the American College of Cardiology (ACC)/American Heart Association (AHA).<sup>26,76,78,80</sup> These latter societies also endorse ExECG as an appropriate indication in asymptomatic patients before cardiac rehabilitation and before initiation of an unsupervised exercise programme.<sup>4</sup> Of note, reassessment of functional capacity during (namely after) the cardiac rehabilitation programme should also be structured to analyze patient gains while also keeping in consideration the quality indicators proposed by the EAPC.<sup>76,77</sup>

Exercise stress testing should be undertaken in patients with heart failure or hypertrophic cardiomyopathy before exercise.<sup>26,37</sup> In these, CPET also takes a prime place because of its ability to provide extensive data which could be used for both prognostic purposes and exercise prescription.<sup>26,37</sup> Nonetheless, ExECG may also be of interest as the presence of symptoms, arrhythmias, and reductions in systolic BP has been used in stratifying risk.<sup>26,37</sup>

### **Valvular heart disease**

In valvular heart disease, exercise testing may be used to objectively assess symptom status (in patients who refer being asymptomatic) and to assist in exercise counseling.<sup>26,42,62</sup> For the former, ExECG is particularly helpful in aortic stenosis.<sup>42,62,81</sup> It should be recalled that in aortic stenosis, mortality is substantially related to the development of symptoms.<sup>82</sup> These may, however, sometimes be challenging to ascertain.<sup>81,82</sup> In this setting, exercise testing can be useful in those with asymptomatic severe aortic stenosis.<sup>42,62,81,83</sup> This concept has been incorporated in guidelines from both the ESC and the ACC/AHA.<sup>42,62</sup> In the former, intervention is recommended in asymptomatic patients with severe aortic stenosis who develop symptoms (class I, level C recommendation) while this should be considered in those with a sustained (above 20 mmHg) decrease in systolic BP during the test (class IIa, level C recommendation).<sup>42</sup> In the latter, exercise testing is deemed as reasonable to assess symptom status and physiological changes in those with asymptomatic severe aortic stenosis (class IIa, level B-NR recommendation).<sup>62</sup> While exercise testing may thus merit consideration when assessing severe asymptomatic aortic stenosis, it should be emphasized that it should be performed by experienced individuals and that this should not be undertaken in those with severe symptomatic aortic stenosis (being an absolute contraindication) given the risk of hemodynamic compromise.<sup>52,62</sup>

Though outside the scope of this report, combining exercise testing with imaging (namely echocardiography) may also provide useful insights into valvular heart disease, such as mitral valve disease.<sup>42,84</sup>

### Conduction, HR, and rhythm monitoring

The ECG is crucial in the management of rhythm disorders, and a dynamic approach (by means of exercise) may be of added value in several clinical contexts.<sup>15,17,39,40,61</sup> Among these, the assessment of the HR response, changes in heart rhythm, and derangements in the conduction of electrical signals are some of the possible targets of ExECG.<sup>15,39,40,61</sup>

As mentioned above, during exercise, HR is expected to progressively increase to allow for a continuous cardiovascular adaptation to shifting metabolic requirements.<sup>17,30,34</sup> An abnormal HR response may be a cause of cardiovascular limitation to effort, and ExECG can be pivotal in this setting.<sup>15,85,86</sup> In this regard, chronotropic incompetence comprises an inability to increase HR during exertion and may be defined as an inability to reach at least 80% of expected HR reserve.<sup>15,61,85</sup> The guidelines from both the ESC and the ACC/AHA (these in conjunction with the Heart Rhythm Society [HRS]) recommend the use of ExECG in those with suspected chronotropic incompetence to aid in diagnosis (both as a class IIa, level B recommendation).<sup>15,61</sup> Beyond its diagnostic role, the ExECG may also be of use in addressing prognosis.<sup>61,85,87</sup> It should be recalled, however, that these data need careful clinical correlation because there are several potential causes of chronotropic incompetence ranging from medications to comorbidities.<sup>15,86,87</sup>

ExECG can also be highly relevant in the study of heart rhythm and conduction disturbances.<sup>15,39,61</sup> When symptoms potentially attributable to these (such as syncope, dyspnea, or chest pain) develop during exertion, ExECG may help unveil the underlying cause.<sup>15,39,61</sup> An example of this can be illustrated in the reproduction of symptoms with the development of advanced heart block during exercise testing, thus providing a correlation between symptoms and conduction anomalies.<sup>88</sup> The ESC guidelines on cardiac pacing and cardiac resynchronization therapy recommend exercise testing in those presenting symptoms compatible with bradycardia during (or immediately after) exertion (class I, level C recommendation) while the ACC/AHA/HRS guidelines state that this is reasonable in this setting (class IIa, level C recommendation).<sup>15,61</sup> These notions are also echoed in the recommendations for those with syncope, which albeit recalling that exercise testing should not be performed in all cases, highlight that it should be considered in those with syncope during (or immediately after) exercise (class I, level C recommendation in the ESC guidelines on this subject).<sup>39</sup>

The analysis of the response of premature ventricular complexes (PVCs) to exercise is also a focus point of current ExECG applications.<sup>26,40,89</sup> Indeed, a decrease in frequency or a suppression of PVCs during exercise is suggestive (in conjunction with other ancillary findings) of a benign nature of these arrhythmias while the induction of PVCs during ExECG should be considered as a “red flag” prompting further workup.<sup>26,89,90</sup> This is underscored in the ESC guidelines on sports cardiology and exercise in patients with CVD, which provide a class I (level C) recommendation for exercise testing in patients with frequent PVCs and nonsustained ventricular tachycardia.<sup>26</sup> While the specificities of the cardiovascular assessment of athletes are beyond the scope of this article, this examination may, nonetheless, be of interest in the workup of those who present frequent PVCs.<sup>26,91,92</sup> Recently, a study on athletes who underwent cardiac magnetic resonance imaging and repeat exercise testing for the study of ventricular arrhythmias also showed that reproducibility of these could refine risk stratification by predicting the presence of an underlying nonischemic left

ventricular scar.<sup>93</sup> On the other hand, although ExECG has been used as a noninvasive tool to analyze the presence of low-risk features in risk stratification of asymptomatic patients with pre-excitation (Wolff-Parkinson-White pattern), its overall place has progressively been challenged.<sup>40,94-98</sup> Contemporary guidance illustrates this notion by providing a stronger recommendation for invasive versus noninvasive assessment in those who are asymptomatic and do not have high-risk occupations or hobbies (IIa versus IIb, respectively; both level B recommendations).<sup>96</sup>

Finally, in those with primary electrical diseases such as the long QT syndrome and catecholaminergic polymorphic ventricular tachycardia, ExECG can provide key diagnostic findings.<sup>40</sup> In the case of the long QT syndrome, the 4-minute recovery (i.e., after exercise) QTc can be incorporated in diagnostic criteria, further reinforcing the notion that not only exercise but also recovery parameters of ExECG can be particularly relevant.<sup>40,99</sup> When assessing the Brugada pattern, a study on 74 patients who performed ExECG also showed that applying high precordial leads could improve diagnostic yield.<sup>100</sup> Interestingly, when considering interventions such as the implantation of a subcutaneous implantable cardioverter-defibrillator (namely in patients with Brugada syndrome), ExECG may also be useful in the screening process of potential candidates.<sup>41,101,102</sup> By analyzing ST-T segment changes during exercise, this framework may allow refinements in the approach to these patients as to avoid the occurrence of possible inappropriate therapies.<sup>102,103</sup>

### Functional capacity

Several studies have provided data on the interplay between functional capacity and the risk of events, across different populations.<sup>17,71,104,105</sup> While this concept is not novel, the recognition of CRF as a powerful variable in risk assessment has prompted a renewed interest.<sup>105,106</sup> Although there are several possible methodologies to infer CRF, the use of ExECG may be helpful to provide an objective measure of this important parameter.<sup>105,107</sup> While in this context, CPET can provide a highly precise estimate of CRF by means of the peak oxygen consumption (among other parameters), ExECG may also be of value by the assessment of metabolic equivalents of task (METs, wherein one MET equates to approximately 3.5 mL/kg/min of oxygen consumption).<sup>105</sup> Importantly, an inverse association between the level of METs obtained during stress testing and events has been described in different studies.<sup>104,105,107</sup>

In this context, ExECG may be useful in the workup of patients with cardiomyopathy (although, also in this setting, the added value of CPET should be pondered with).<sup>108</sup>

Importantly, the application of ExECG for functional assessment intersects deeply with several others, most notably those related to exercise prescription counseling and the integrated analysis of the cardiovascular system (whose physiological response is necessary for adequate CRF).

### Current challenges and future perspectives

Beyond the classical use of ExECG in the diagnostic process of IHD, there are several scenarios in which this examination can provide valuable data, with the potential to affect clinical care.<sup>4,16,26,39,40,42,48,57,61,62</sup> Although some issues remain regarding the optimal implementation of this methodology across different momentums of the cardiovascular continuum, namely in the face of

the progressive evolution of novel diagnostic methods, current data, nevertheless, attest to its continuous utility.<sup>17,40,42,89,93</sup>

In an era where contributions from different areas progressively and rapidly lead to marked changes in the approach to CVD, ExECG has stood the test of time as a pivotal test in cardiovascular medicine.<sup>4,17,26,40,57,109</sup> Among some of the challenges to be faced, the incorporation of new technologies (such as those encompassing artificial intelligence) could further change the landscape by optimizing its assessment and scope.<sup>23,110,111</sup> Indeed, as digital tools become increasingly intertwined with several diagnostic modalities, so too may ExECG be affected by these applications.<sup>11,110-112</sup>

When considering ExECG in contemporary settings, an integrated assessment should be undertaken focusing not only on the ST segment but also on all the different and interlinked components that take part in the cardiovascular response to exercise and can be dynamically influenced by pathologic processes.<sup>17,30,31,52</sup> In this way, data derived from this complex examination can be streamlined as to improve its applicability and relevance while harnessing its full potential.<sup>52</sup> As elegantly stated approximately thirty years ago by Kliegfield and Okin<sup>113</sup> in a classical editorial concerning the (then) evolution of ExECG and commenting on different algorithms for improved test performance, “*first it must be perceived that the exercise tolerance test is capable of change.*”

## Conclusion

ExECG has evolved substantially in parallel to the major improvements across cardiovascular care in general. Since the dawn of the Bruce protocol 60 years ago, this examination has continuously proven to be of substantial value across several pathologies. Albeit its many limitations, the ability to provide a dynamic assessment of different components of the cardiovascular response to exercise makes it particularly suitable in various clinical contexts. As medicine becomes increasingly personalized, with the focus on a comprehensive and integrative approach to CVD taking an ever more prominent center stage, ExECG is at present set to remain at the forefront of optimal cardiovascular care.

## References

- [1] Tsao CW, Aday AW, Almarzoq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. *Circulation*. 2023;147:e93–e621.
- [2] Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2020;395:785–794.
- [3] Braunwald E. The rise of cardiovascular medicine. *Eur Heart J*. 2012; 33:838–845.
- [4] Winchester DE, Maron DJ, Blankstein R, et al. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multimodality appropriate use criteria for the detection and risk assessment of chronic coronary disease. *J Am Coll Cardiol*. 2023;81:2445–2467.
- [5] Lindstrom M, DeCleene N, Dorsey H, et al. Global burden of cardiovascular diseases and risks collaboration, 1990-2021. *J Am Coll Cardiol*. 2022;80:2372–2425.
- [6] Sinagra G, Fabris E, Tavazzi L. The evolution of cardiology: changes, future challenges and opportunities. *Future Cardiol*. 2017;13:161–171.
- [7] Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021; 42:3227–3337.
- [8] Antonini-Canterin F, Faganello G, Mantero A, et al. Cardiovascular multimodality imaging: It Is Time to Get on Board! A "Società Italiana di Ecocardiografia e CardioVascular Imaging" Statement. *J Cardiovasc Echogr*. 2018;28:1–8.
- [9] Stillman AE, Oudkerk M, Bluemke DA, et al. Imaging the myocardial ischemic cascade. *Int J Cardiovasc Imaging*. 2018;34:1249–1263.
- [10] Vilela EM, Fontes-Carvalho R. Left ventricular mechanics: untwisting the pathways of the cardiovascular response to exercise. *Arq Bras Cardiol*. 2023;120:e20230181.
- [11] Kashou AH, May AM, Noseworthy PA. Artificial intelligence-enabled ECG: a modern lens on an old technology. *Curr Cardiol Rep*. 2020;22:57.
- [12] AlGhatrif M, Lindsay J. A brief review: history to understand fundamentals of electrocardiography. *J Community Hosp Intern Med Perspect*. 2012;2(1):1–5.
- [13] Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. *Eur Heart J*. 2023. In press.
- [14] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. 2019;40:237–269.
- [15] Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J*. 2021;42:3427–3520.
- [16] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–477.
- [17] Sharma K, Kohli P, Gulati M. An update on exercise stress testing. *Curr Probl Cardiol*. 2012;37:177–202.
- [18] Stracina T, Ronzhina M, Redina R, Novakova M. Golden standard or obsolete method? Review of ECG applications in clinical and experimental context. *Front Physiol*. 2022;13:867033.
- [19] Bruce RA. Improvements in exercise electrocardiography. *Circulation*. 1989;79:458–459.
- [20] Master AM, Friedman R, Dack S. The electrocardiogram after standard exercise as a functional test of the heart. *Am Heart J*. 1942;24:777–793.
- [21] Tamis-Holland JE. Surveillance stress testing "POST-PCI"—a future class III recommendation? *N Engl J Med*. 2022;387:941–942.
- [22] Bruce RA, Blackmon JR, Jones JW, Strait G. Exercising testing in adult normal subjects and cardiac patients. *Pediatrics*. 1963;32:742–56.
- [23] Shah BN. On the 50th anniversary of the first description of a multistage exercise treadmill test: re-visiting the birth of the 'Bruce protocol.' *Heart*. 2013;99:1793–1794.
- [24] Fontes-Carvalho R, Vilela EM, Gonçalves-Teixeira P. The effect of exercise training in systolic and diastolic function. In: Watson RR, Zibadi S, eds. *Lifestyle in heart health and disease*. 1st ed. Amsterdam: Elsevier; 2018:153–62.
- [25] Valenzuela PL, Ruilope LM, Santos-Lozano A, et al. Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation. *Eur Heart J*. 2023;44:1874–1889.
- [26] Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J*. 2021;42:17–96.
- [27] Vilela EM, Ladeiras-Lopes R, Joao A, et al. Current role and future perspectives of cardiac rehabilitation in coronary heart disease. *World J Cardiol*. 2021;13:695–709.
- [28] Vilela EM, Bastos JC, Rodrigues RP, Nunes JP. High-sensitivity troponin after running—a systematic review. *Neth J Med*. 2014;72:5–9.
- [29] Moreira JBN, Wohlwend M, Wisloff U. Exercise and cardiac health: physiological and molecular insights. *Nat Metab*. 2020;2:829–839.
- [30] D'Silva A, Sharma S. Cardiovascular response induced by exercise. In: Pelliccia A, Heidbuchel H, Corrado D, Borjesson M, Sharma S, eds. *ESC textbook sports cardiology*. 1st ed. UK: OUP; 2019:3–8.
- [31] Guazzi M, Adams V, Conraads V, et al. EACPR/AHA Joint Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Eur Heart J*. 2012;33:2917–2927.
- [32] Baggish AL, Battle RW, Beaver TA, et al. Recommendations on the use of multimodality cardiovascular imaging in young adult competitive athletes: a report from the American Society of Echocardiography in collaboration with the Society of Cardiovascular Computed Tomography and the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr*. 2020;33:523–549.
- [33] Husaini M, Emery MS. Cardiopulmonary exercise testing interpretation in athletes: what the cardiologist should know. *Cardiol Clin*. 2023;41:71–80.
- [34] Smarż K, Jaxa-Chamiec T, Chwyczo T, et al. Cardiopulmonary exercise testing in adult cardiology: expert opinion of the working Group of cardiac rehabilitation and exercise Physiology of the polish cardiac society. *Kardiologia Pol*. 2019;77:730–756.
- [35] van de Vegte YJ, Teegene BS, Verweij N, Snieder H, van der Harst P. Genetics and the heart rate response to exercise. *Cell Mol Life Sci*. 2019; 76:2391–2409.

- [36] Hawkins S, Wiswell R. Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training. *Sports Med.* 2003;33:877–888.
- [37] Gati S, Sharma S. Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know. *Heart.* 2022;108:1930–1937.
- [38] Priel E, Wahab M, Mondal T, et al. The Impact of beta blockade on the cardio-respiratory system and symptoms during exercise. *Curr Res Physiol.* 2021;4:235–242.
- [39] Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope. *Eur Heart J.* 2018;39:1883–1948.
- [40] Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J.* 2022;43:3997–4126.
- [41] Dendramis G, Brugada P. Lights and shadows of subcutaneous implantable cardioverter-defibrillator in Brugada syndrome. *Heart Rhythm.* 2023;20:274–281.
- [42] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J.* 2022;43:561–632.
- [43] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J.* 2018;39:3021–3104.
- [44] Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). *J Hypertens.* 2023. In press.
- [45] Kokkinos P, Faselis C, Sidossis L, et al. Exercise blood pressure, cardiorespiratory fitness and mortality risk. *Prog Cardiovasc Dis.* 2021;67:11–17.
- [46] Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. *Eur Respir Rev.* 2021;30:200187.
- [47] Vilela EM, Ladeiras-Lopes R, João A, et al. Cardiac rehabilitation in elderly myocardial infarction survivors: focus on circulatory power. *Rev Cardiovasc Med.* 2021;22:903–910.
- [48] Hansen D, Abreu A, Ambrosetti M, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol.* 2022;29:230–245.
- [49] Guazzi M, Wilhelm M, Halle M, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy—A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. *Eur J Heart Fail.* 2022;24:1327–1345.
- [50] Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation.* 2019;139:e997–e1012.
- [51] Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1997 exercise testing guidelines). *Circulation.* 2002;106:1883–92.
- [52] Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation.* 2013;128:873–934.
- [53] Bousfield G. Angina pectoris: changes in electrocardiogram during paroxysm. *Lancet.* 1918;2:457–458.
- [54] Kennedy JW, Cobb LA, Samson WE, Robert Arthur Bruce, MD. Exercise cardiology. *Circulation.* 2005;111:2410–2411.
- [55] Tannen T, Robert A Bruce. *Lancet.* 2004;363:1403.
- [56] Ritchey MD, Wall HK, George MG, Wright JS. US trends in premature heart disease mortality over the past 50 years: where do we go from here? *Trends Cardiovasc Med.* 2020;30:364–374.
- [57] Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2021;78:e187–e285.
- [58] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J.* 2013;34:2949–3003.
- [59] Nakano S, Kohsaka S, Chikamori T, et al. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. *Circ J.* 2022;86:882–915.
- [60] Bettencourt N, Mendes L, Fontes JP, et al. Consensus document on chronic coronary syndrome assessment and risk stratification in Portugal: a position paper statement from the [Portuguese Society of Cardiology's] working groups on Nuclear Cardiology, Magnetic Resonance and Cardiac Computed Tomography, Echocardiography, and Exercise Physiology and Cardiac Rehabilitation. *Rev Port Cardiol.* 2022;41:241–251.
- [61] Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019;74:e51–e156.
- [62] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2021;77:e25–e197.
- [63] Singh T, Bing R, Dweck MR, et al. Exercise electrocardiography and computed tomography coronary angiography for patients with suspected stable angina pectoris: a post hoc analysis of the randomized SCOT-HEART trial. *JAMA Cardiol.* 2020;5:920–928.
- [64] Zacharias K, Ahmed A, Shah BN, et al. Relative clinical and economic impact of exercise echocardiography vs. exercise electrocardiography, as first line investigation in patients without known coronary artery disease and new stable angina: a randomized prospective study. *Eur Heart J Cardiovasc Imaging.* 2017;18:195–202.
- [65] Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. *Eur Heart J.* 2018;39:3322–3330.
- [66] Papachristidis A, Vaughan GF, Denny SJ, et al. Comparison of NICE and ESC proposed strategies on new onset chest pain and the contemporary clinical utility of pretest probability risk score. *Open Heart.* 2020;7:e001081.
- [67] Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2023;82:833–955.
- [68] Shaw LJ, Mieres JH, Hendel RH, et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the what Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. *Circulation.* 2011;124:1239–49.
- [69] Gurunathan S, Shanmuganathan M, Chopra A, et al. Comparative effectiveness of exercise electrocardiography versus exercise echocardiography in women presenting with suspected coronary artery disease: a randomized study. *Eur Heart J Open.* 2023;3:oead053.
- [70] Marcadet DM, Pavy B, Bosser G, et al. French Society of Cardiology guidelines on exercise tests (part 1): methods and interpretation. *Arch Cardiovasc Dis.* 2018;111:782–790.
- [71] Bourque JM, Beller GA. Value of exercise ECG for risk stratification in suspected or known CAD in the era of advanced imaging technologies. *JACC Cardiovasc Imaging.* 2015;8:1309–1321.
- [72] Daubert MA, Sivak J, Dunning A, et al. Implications of abnormal exercise electrocardiography with normal stress echocardiography. *JAMA Intern Med.* 2020;180:494–502.
- [73] Fitzgerald BT, Smith E, Scalia GM. What are the prognostic implications and factors relating to exercise induced electrocardiographic ST segment changes in the setting of a non-ischemic stress echocardiogram? *Int J Cardiol.* 2022;364:157–161.
- [74] Lopez DM, Divakaran S, Gupta A, et al. Role of exercise treadmill testing in the assessment of coronary microvascular disease. *JACC Cardiovasc Imaging.* 2022;15:312–321.
- [75] Mansour M, Alqaisi O, Malkawi A, et al. Significance of indeterminate and abnormal stress electrocardiography despite normal imaging in

- patients with suspected coronary artery disease - an analysis of the PROMISE trial. *J Electrocardiol.* 2022;73:79–86.
- [76] Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: the avenue towards EAPC accreditation programme: a position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). *Eur J Prev Cardiol.* 2021;28:496–509.
- [77] Abreu A, Mendes M, Dores H, et al. Mandatory criteria for cardiac rehabilitation programs: 2018 guidelines from the Portuguese Society of Cardiology. *Rev Port Cardiol (Engl Ed).* 2018;37:363–373.
- [78] Thompson PD, Myerburg RJ, Levine BD, Udelson JE, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 8: coronary artery disease: a scientific statement from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol.* 2015;66:2406–2411.
- [79] Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J.* 2023. In press.
- [80] Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). *Eur Heart J.* 2019;40:13–18.
- [81] Chambers JB. Educational series on the specialist valve clinic: how to run a specialist valve clinic: the history, examination and exercise test. *Echo Res Pract.* 2019;6:T23–T28.
- [82] Carabello BA. Introduction to aortic stenosis. *Circ Res.* 2013;113:179–185.
- [83] Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation.* 1997;95:2262–2270.
- [84] Citro R, Bursi F, Bellino M, Picano E. The role of stress echocardiography in valvular heart disease. *Curr Cardiol Rep.* 2022;24:1477–1485.
- [85] Zweerink A, van der Lingen ACJ, Handoko ML, van Rossum AC, Allaart CP. Chronotropic incompetence in chronic heart failure. *Circ Heart Fail.* 2018;11:e004969.
- [86] Tanayan C, Reddy S, Shah AB, Wasfy MM. A cyclist on a tricyclic: exercise intolerance due to chronotropic incompetence. *JACC Case Rep.* 2022;4:1335–1340.
- [87] Akcakoyun M, Emiroglu Y, Pala S, et al. Heart rate recovery and chronotropic incompetence in patients with subclinical hypothyroidism. *Pacing Clin Electrophysiol.* 2010;33:2–5.
- [88] Vilela EM, Torres S, Gonçalves H, Primo J, Teixeira M, Braga P. Complete atrioventricular block during exercise: new insights from an old test. *Monaldi Arch Chest Dis.* 2019;89(1):91–94.
- [89] Corrado D, Drezner JA, D'Ascenzi F, Zorzi A. How to evaluate premature ventricular beats in the athlete: critical review and proposal of a diagnostic algorithm. *Br J Sports Med.* 2020;54:1142–1148.
- [90] Kasiakogias A, Papadakis M. Morphology of premature ventricular complexes: time for a paradigm shift in the approach of ventricular ectopy in athletes? *Eur J Prev Cardiol.* 2021;28:1035–1037.
- [91] Mont L, Pelliccia A, Sharma S, et al. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. *Eur J Prev Cardiol.* 2017;24:41–69.
- [92] Sharma S, Drezner JA, Baggish A, et al. International recommendations for electrocardiographic interpretation in athletes. *Eur Heart J.* 2018;39:1466–1480.
- [93] Brunetti G, Graziano F, Cavigli L, et al. Reproducibility of ventricular arrhythmias at exercise testing for prediction of non-ischaemic left ventricular scar in athletes. *Eur J Prev Cardiol.* 2023;30:107–116.
- [94] Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. *J Am Coll Cardiol.* 2003;42:1493–1531.
- [95] Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2016;67:e27–e115.
- [96] Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). *Eur Heart J.* 2020;41:655–720.
- [97] Leung LWM, Gallagher MM. Review paper on WPW and athletes: let sleeping dogs lie? *Clin Cardiol.* 2020;43:897–905.
- [98] Escudero CA, Ceresnak SR, Collins KK, et al. Loss of ventricular preexcitation during noninvasive testing does not exclude high-risk accessory pathways: a multicenter study of WPW in children. *Heart Rhythm.* 2020;17:1729–1737.
- [99] Kaufman ES, Eckhardt LL, Ackerman MJ, et al. Management of congenital long-QT syndrome: commentary from the experts. *Circ Arrhythm Electrophysiol.* 2021;14:e009726.
- [100] Pichara NL, Sacilotto L, Scanavacca MI, et al. Evaluation of a new treadmill exercise protocol to unmask type 1 Brugada electrocardiographic pattern: can we improve diagnostic yield? *Europace.* 2023;25:euaad157.
- [101] Tachibana M, Nishii N, Morita H, et al. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. *J Cardiovasc Electrophysiol.* 2017;28:1454–1459.
- [102] von Hafe P, Faria B, Dias G, et al. Brugada syndrome: eligibility for subcutaneous implantable cardioverter-defibrillator after exercise stress test. *Rev Port Cardiol (Engl Ed).* 2021;40:33–38.
- [103] Świerżyńska E, Sterliński M, Syska P, Sadowski K, Szumowski Ł. Use of an exercise test to enhance sensing vector assessment and prevent inadequate subcutaneous implantable cardioverter-defibrillator discharges. *J Electrocardiol.* 2021;67:73–76.
- [104] Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. *JAMA Netw Open.* 2018;1:e183605.
- [105] Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. *Circulation.* 2016;134:e653–e699.
- [106] Franklin BA, Eijssvogels TMH, Pandey A, Quindry J, Toth PP. Physical activity, cardiorespiratory fitness, and cardiovascular health: a clinical practice statement of the ASPC Part I: bioenergetics, contemporary physical activity recommendations, benefits, risks, extreme exercise regimens, potential maladaptations. *Am J Prev Cardiol.* 2022;12:100424.
- [107] Hung RK, Al-Mallah MH, McEvoy JW, et al. Prognostic value of exercise capacity in patients with coronary artery disease: the FIT (Henry Ford Exercise Testing) project. *Mayo Clin Proc.* 2014;89:1644–1654.
- [108] Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. *Eur Heart J.* 2023;44:3503–3626.
- [109] Vilela E, Fontes-Carvalho R. Medical practice in a changing world: reflections from the 19th century. *JACC Case Rep.* 2022;4:832–834.
- [110] Yilmaz A, Hayiroğlu Mİ, Salturk S, et al. Machine learning approach on high risk treadmill exercise test to predict obstructive coronary artery disease by using P, QRS, and T waves' features. *Curr Probl Cardiol.* 2023;48:101482.
- [111] Zheng C, Sun BC, Wu YL, et al. Automated identification and extraction of exercise treadmill test results. *J Am Heart Assoc.* 2020;9:e014940.
- [112] Koulaouzidis G, Jadczyk T, Iakovidis DK, Koulaouzidis A, Bisnaire M, Charisopoulou D. Artificial intelligence in cardiology-A narrative review of current status. *J Clin Med.* 2022;11:3910.
- [113] Kligfield P, Okin PM. Evolution of the exercise electrocardiogram. *Am J Cardiol.* 1994;73:1209–1210.